clinicaltrials.gov
Feed RSS ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days
Dapatkan update terbaru dari ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days langsung begitu tersedia.
Postingan terbaru
Dapatkan ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days di tempat Anda membaca
Orang yang mengikuti ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days juga mengikuti
-
Chugai Pharmaceutical: News Releases chugai-pharm.co.jp
-
Bristol Myers Squibb Press Releases news.bms.com
-
Regeneron Pharmaceuticals Inc. News Releases investor.regeneron.com
-
What's new ema.europa.eu
Pertanyaan
Apa URL feed RSS untuk ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days?
Alamat feed-nya adalah https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=&lup_d=14&sel_rss=mod14&term=mezagitamab+%28TAK+079%29&recrs=abdf&type=Intr&phase=0124&fund=2&count=10000. Tempelkan ke pembaca RSS apa pun, atau klik Ikuti sekarang untuk membacanya di Feeder.
Seberapa sering ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days memposting?
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days memposting kurang dari sekali seminggu. Postingan terakhir diterbitkan 12 hari lalu.
Apakah feed RSS ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days berfungsi?
Ya. Feeder memeriksanya sekitar 1 jam lalu dan feed merespons secara normal.
Bagaimana cara mengikuti ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days di Feeder?
Klik Ikuti sekarang, lalu daftar jika Anda belum memiliki akun. Paket gratis Feeder mencakup hingga 200 feed, di web, iPhone, dan Android. Tidak memerlukan kartu kredit.
Ikuti ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days di Feeder
Paket gratis Feeder mencakup hingga 200 feed, di web, iPhone, dan Android. Tidak memerlukan kartu kredit.